A defensive moat, built one granted patent at a time.
Miragen's platforms sit behind two granted Indian patents and an active pipeline, with Freedom-to-Operate analysis confirming differentiated mechanisms against incumbent technologies.
Granted Patent No. 408307
Nanoparticles Incorporated Self-Gelling Composition as Drug Delivery System
In-situ gelation mechanism — a composition transitioning from liquid to gel phase upon physiological contact (thermosensitive / pH-responsive), enabling minimally invasive injection.
Nanoparticle embedding technology — a method of incorporating polymeric nanoparticles within the gel matrix without compromising particle integrity or gel stability.
Controlled release profile — sustained release kinetics via dual-barrier diffusion (nanoparticle core + gel matrix), extending the therapeutic window from days to weeks.
Composition of matter
The specific formulation of polymer, nanoparticles, and gelling agents.
Method of preparation
Proprietary process for fabrication and sterilization.
Method of use
Application for delivering chemotherapeutic agents to resection cavities.
Granted Patent No. 366070
Micronutrient Supplement Lip-Salve Formulation
Lipid nanoparticle mechanism — lipid-based nanoparticles fluidize the stratum corneum, enabling deep follicular and intercellular penetration beyond the dermis.
GRAS material composition — formulated exclusively with Generally Recognized As Safe, biocompatible, biodegradable lipids.
Cosmetic carrier integration — stable integration into cosmetic bases (lip salves, creams) for non-invasive micronutrient delivery.
Nanoparticle formulation
Specific lipid ratios for optimal penetration.
Bio-compatible matrix
GRAS-compliant delivery vehicle.
Transdermal method
System for delivering active nutrients via the skin.
Pipeline in development
Beyond the two granted patents, Miragen's R&D continues toward additional filings covering SPR chip design and microfluidics, BBB-penetrating nanotube formulations, and microneedle patch compositions — expanding the portfolio into early cancer detection devices and non-invasive brain delivery.
A rigorous Freedom-to-Operate analysis confirms differentiated mechanisms versus incumbent technologies, with an international filing strategy targeting key markets (US, EU) for the nanotube and biosensor platforms.
| Incumbent | Miragen (Protected) |
|---|---|
| Gliadel® Wafer — rigid surgical implant | Injectable, liquid-to-gel, conforms to cavity |
| Standard liposomes — surface delivery | Deep penetration, >200µm follicular targeting |
FTO assessment finds no infringement on key patents; GRAS-material use simplifies the regulatory path versus complex chemical-entity patents.
How the IP portfolio can be engaged
Exclusive or non-exclusive
Patent rights can be licensed on an exclusive or non-exclusive basis, typically ranging ₹10–85L depending on scope and territory.
Full GMP package
A complete technology transfer package includes manufacturing process, quality specifications, and hands-on GMP scale-up support.